Ignyta, a San Diego-based precision oncology biotechnology company, announced it has been added to the widely followed Russell 2000 Index of small-cap stocks.

The company was added to the index at the close of trading on Friday. Ignyta also recently announced a $75 million offering of common stock.

Ignyta is developing new drugs that target activated cancer genes and pathways for the customized treatment of cancer, as well as novel chemotherapy that can potentially provide additional benefit to cancer patients.

For the 2014 fiscal year, the company reported a net loss was $40.0 million as it focused on developing a series of new drugs, several of which are already in clinical trials.

Show comments

Chris Jennewein

Chris Jennewein is Editor & Publisher of Times of San Diego.